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There is limited information about the role of protocol kidney biopsies for de novo donor-specific antibodies (dnDSA) in kidney transplant recipients, especially in those with stable graft function. We initiated a routine posttransplant DSA monitoring and surveillance biopsy program for dnDSA since 2014. We identified 45 kidney transplant recipients with dnDSA detected between January 2014 and February 2017 who underwent kidney biopsy within 60 days of detection of dnDSA. Twenty-nine (64%) had stable graft function and 16 (36%) had impaired graft function at the time of dnDSA detection. Even in the group with stable graft function, we found a high rate of rejection (53%) on biopsy. Eighty-eight percent of patients with impaired graft function had rejection. Those patients with impaired graft function had significantly lower estimated glomerular filtration rate at 12 months postbiopsy and at last follow-up.
Those with impaired graft function had more graft failures; however, this result was not statistically significant. The high rate of asymptomatic rejection, and the fact that outcomes in asymptomatic patients are poor, is in support of the utility of surveillance biopsies in patients with dnDSA.
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| INTRODUCTION
Over one fifth of the patients on the kidney transplant waitlist have preexisting antibodies directed against human leukocyte antigens (HLA) with calculated panel reactive antibodies (cPRA) of more than 80%. 1 The presence of pretransplant donor-specific antibodies (DSA)
is associated with increased risk of antibody-mediated rejection (AMR). The incidence of AMR in patients with preexisting DSA is 9-fold higher than in patients without DSA, resulting in worse graft outcomes. 2 Even after kidney transplantation, significant numbers of recipients have DSA. Patients with suboptimal renal function and who develop de novo DSA (dnDSA) have higher rates of graft loss at 2 years compared to those without antibodies. 3 In another study, 10-year median graft survival among patients who develop dnDSA was 57%, significantly lower than those without dnDSA at 96% (P < .001). 4 Several additional studies have suggested dnDSA as a prognostic biomarker for predicting poor graft survival. 5, 6 Among previously unsensitized patients, dnDSA against HLA class II predominate in renal transplant recipients. 7 Donor HLA-DR mismatch and nonadherence to immunosuppressive medications have been shown to be strong predictors of development of dnDSA followed by rejection. 4 The evolution of more sensitive and specific assays for DSA in kidney transplant recipients, and uncertainty about the role of biopsy. In this study, we report the rate and types of rejection associated with the development of dnDSA, and demonstrate the utility of protocol biopsies.
| METHODS

| Patients
We evaluated all patients at the University of Wisconsin who had a kidney transplant and underwent protocol DSA testing after January 1, 2014. Those included in this study had dnDSA detected between January 1, 2014 and February 28, 2017 and transplantation any time prior. We included in the analysis only those patients with dnDSA who had a renal biopsy within 60 days of detection of dnDSA (n = 45). for urine protein-to-creatinine ratios (UPC) when urine protein was undetectable. We defined impaired renal function as serum creatinine more than 25% above baseline or new proteinuria. New proteinuria was defined as UPC > 0.5 if the baseline was below 0.5, or a doubling of UPC at time of dnDSA detection if the baseline UPC was ≥ 0.5.
| Study protocol and data collection
Graft loss was defined as return to dialysis, retransplantation, or patient death. "Reduced immunosuppression" was defined as immunosuppression below protocol, which was used clinically for infections such as BK virus or cytomegalovirus, or medication side effects, and was also seen with medication noncompliance. Our usual immunosuppression regimen is tacrolimus (12-hour trough goal of 5-7 ng/dL after 6 months posttransplant), mycophenolic acid 720 mg twice a day, and prednisone 5 mg daily, with doses adjustments for side effects and immunological risk.
| Rejection pathology
All rejections were defined by biopsy using Banff 2013 criteria.
Borderline changes for rejection were considered rejection in this study, but only 2 biopsies were read as borderline, 1 in each group.
Microvascular injury score was defined as the peritubular capillaritis score plus the glomerulitis score. Chronicity score was defined as the interstitial fibrosis score plus the tubular atrophy score plus the fibrous intimal thickening score plus the allograft glomerulopathy score on microscopy. 
| Kidney rejection treatment
Our AMR treatment protocols were based on severity of rejection and 
| Statistical analyses
All statistical analyses were performed using R version 3. with log-rank test was used to assess graft survival. Graft survival analyses were truncated at 5 years of follow-up, as the vast majority of events were reached by this time.
| RESULTS
| Patient demographics
Patient demographics are listed in Table 1 . We identified 51 patients who developed dnDSA post renal transplant during the study period, of which 45 had a graft kidney biopsy within 2 months of detection of dnDSA. We included these 45 patients in this study. Of the 6 patients without biopsy, 2 were managed with active surveillance due to lowlevel DSA (MFI sum of less than 500), which became negative when (Table 1) .
| Comparison of patients with stable versus impaired graft function at the time of dnDSA detection
Twenty-nine patients had stable graft function at baseline and 16
patients had impaired graft function at the time of dnDSA detection ( interval from dnDSA detection to biopsy was significantly shorter in the groups of patients with impaired graft function at time of dnDSA detection (median 1 vs 11 days; P = .0014; Table 2 ). All but 6 patients were on tacrolimus at the time of dnDSA detection. Three were on cyclosporine and 3 were on belatacept. Two were on cyclosporine and 2
were on belatacept in the stable group; 1 was on cyclosporine and 1 on belatacept in the impaired graft function group. The number of patients with reduced immunosuppression was similar between the stable and impaired graft function groups (24% vs 44%, P = .20; Table 2 ). The mean class I pretransplant PRA was significantly higher in the stable compared with the impaired graft function group (mean 16% vs 0%, P = .03; Table 2 ); however, there was no difference in the mean class II pretransplant PRA between the groups (Table 2 ). All other baseline characteristics were similar between the 2 groups ( Table 2 ).
| dnDSA antibody characteristics
The characteristics of the dnDSA in patients with stable versus impaired graft function at the time of dnDSA detection are shown in Table 3 . The frequencies of class I only, class II only, or class I and II dnDSA were similar between the groups. The mean MFI sum values for dnDSA were also similar between the groups. In 4 of 14 patients with stable renal function and no rejection, DSA was undetectable on repeat analysis after increasing maintenance immunosuppression.
| Rejection and histological characteristics
The proportion of patients with rejection on biopsy was lower in the stable graft function than in the impaired graft function group at time of dnDSA detection (52% compared with 88%, P = .023; Tables 2 and   3 ). Nevertheless, the proportion of patients with stable graft function yet rejection on biopsy was quite high (52%). Interestingly, there was a mixture of AMR, ACR, and mixed rejection found on biopsy (Table 3 ).
In patients with stable graft function, 20% had ACR, 60% had AMR, and 20% had mixed rejection, and in the group of patients with impaired graft function, 43% had ACR, 14% had AMR, and 43% had mixed rejection on biopsy (P = .044; Table 3 ). The microvascular injury, chronicity, and C4d scores on histology were similar between the 2 groups (Table 3) . Table 4 shows the serum creatinine, eGFR, and UPC at the time of T A B L E 3 dnDSA characteristics and outcomes in patients with stable versus impaired renal function at time of detection of dnDSA Bold values are statistically significant. Cr, creatinine; eGFR, estimated glomerular filtration rate; SD, standard deviation; UPC, urine protein-to-creatinine ratio.
| Clinical characteristics and graft survival in patients with stable vs impaired graft function
vs. 29.1 ± 18.6 mL/min/1.73 m², P = .003; Table 4 ). UPC was higher in the impaired graft function at time of biopsy, but the difference was not statistically significant (mean UPC: 0.3 ± 0.3 compared with 1.2 ± 2.8, P = .10; Table 4 ). Of those with impaired graft function at dnDSA detection and rejection on biopsy, 14/14 (100%) had elevated creatinine and 10/14 (71%) had higher UPC at dnDSA detection. eGFR 12 months postbiopsy was significantly higher in the group of patients with stable graft function (mean eGFR: 44.8 ± 18.9 mL/min/1.73 m² compared with 20.8 ± 14.9 mL/min/1.73 m², P = .037; Table 4 ). eGFR at last available follow-up was also significantly higher in patients with stable graft function (mean eGFR: 49.04 ± 22.45 mL/min/1.73 m² compared with 33.7 ± 24.5 mL/min/1.73 m², P = .03; Table 4 ). UPC
was not different between the 2 groups at last follow-up (mean UPC:
0.4 ± 0.9 compared with 1.1 ± 1.9, P = .18; Table 4 ). There were only 4 graft failures in the study period; 1 occurred in the group with stable graft function and 3 occurred in the group with impaired graft function at the time of dnDSA detection (P = .15; Figure 1 ). There were no significant differences in graft survival between patients with ACR, AMR, or mixed rejection (P = .18; Figure 2 ).
| DISCUSSION
In this study, we found a high rate of rejection on kidney biopsies in patients with stable graft function at the time of dnDSA detection (53% , Table 3 (Table 4 ). These patients also have more graft failures (Figure 1 ), although this difference is not statistically significant. Interestingly, the pattern of rejection was different between the 2 groups, with more AMR in the stable function group, but more ACR and mixed rejection in the impaired graft function group. This information about different types of rejection also supports the utility of performing protocol biopsies in these patients.
AMR is a common complication after development of dnDSA.
Schinstock et al noted a significant increase in the rate of AMR from 25% at time of dnDSA detection to 52.9% at 1-year protocol biopsy.
11
However, not all who develop dnDSA have graft damage on biopsy, and mechanisms underlying graft injury from dnDSA are poorly understood. 12, 13 Complement binding of dnDSA, as measured by C1q fixation, C3d-binding activity, and presence of intragraft dnDSA, are all associated with graft injury. [14] [15] [16] Nocera et al noted a 72% rate of intragraft dnDSA among recipients who underwent kidney graft biopsy due to dnDSA and had rejection. Interestingly, intragraft dnDSA homing was similar among patients with antibody-mediated or cellular rejections. 14 A significant number of patients in our cohort had ACR.
Alloantibody and complement deposition on graft endothelial cells can enhance alloreactive T cell activation and allograft vasculopathy.
17
Clinical and translational studies have demonstrated that in patients with AMR, the anti-donor indirect T effector response is increased, whereas the T regulatory (Treg) response is decreased. 18 However, the specific role of Tregs and memory/effector T cells in the pathogenesis of AMR remains unknown.
Many of the patients in this study had subclinical rejections and underwent protocol biopsy solely based on the presence of dnDSA.
While some have argued against treating subclinical rejection, 19, 20 we believe that most of the field is moving toward routinely treating subclinical rejection. A randomized control trial has shown benefit in treating subclinical rejection in terms of histological and functional outcomes, although with a higher rate of infectious complications. 25 Young recipients, patients with a history of T cell-mediated rejection, and HLA-DR dnDSA are associated with the increased risk of subclinical AMR. 26 We believe that the 53% rate of rejection we find here in "asymptomatic" patients supports the current recommendations 27 for routine monitoring of DSA after kidney transplantation. Viglietti et al showed that standardized monitoring of DSA within 2 years after transplantation improved the risk for graft loss.
28
The optimal approach to the treatment of subclinical rejection is unclear, but a common approach is to increase baseline immunosuppressive medication and give a steroid pulse. 29 As future treatments for AMR become increasingly effective, the rationale for protocol biopsies should become even stronger.
All graft biopsies are invasive procedures; however, kidney graft biopsy complications in experienced hands are rare. In our published series of 3738 kidney graft biopsies, the rate of complications was 1.8%. While most complications were mild or moderate, 0.21% had severe complications and 0.19% had life-threatening complications, although no deaths occurred.
30
Limitations of this study include its being limited to a single center. Our study population has mostly white patients and those receiving basiliximab induction and may not be as generalizable to centers treating diverse ethnic populations or using alternate induction regimens. Our study also has a limited sample size due to the strict selection criteria. However, to our best knowledge, ours is the largest reported series of its kind comparing stable and impaired renal function at the time of the detection of dnDSA. Given the limited follow-up, there were few graft failures and conclusions about long-term graft outcomes cannot be ascertained, but the main objective of this study was to find the rate and types of rejections associated with the development of dnDSA, and the utility of protocol kidney graft biopsy.
In summary, there is a substantial incidence of rejection in recipients who developed dnDSA. Even among those with stable graft function, there is a clinically meaningful rate of rejection with a mixture of ACR, AMR, and mixed rejection on biopsy necessitating different types of treatment. These findings support the utility of biopsy in patients with dnDSA.
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